Comparative Pharmacology
Head-to-head clinical analysis: LERIBANE versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LERIBANE versus WILPO.
LERIBANE vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leribane is a synthetic cannabinoid receptor agonist with high affinity for CB1 and CB2 receptors. It inhibits adenylate cyclase activity via Gi/o protein coupling, leading to decreased cAMP accumulation, modulation of ion channels, and inhibition of neurotransmitter release.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
5-10 mg orally twice daily; maximum 30 mg/day.
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
24 hours (range 20-30 h); accumulates to steady state in ~5 days, requires dose adjustment in renal impairment
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown